Maintenance treatment with fluoropyrimidine plus bevacizumab versus fluoropyrimidine alone after induction chemotherapy for metastatic colorectal cancer: The BEVAMAINT - PRODIGE 71 - (FFCD 1710) phase III study.
暂无分享,去创建一个
A. Lièvre | P. Laurent-Puig | C. Lepage | P. Michel | D. Malka | D. Tougeron | T. Aparicio | J. Phelip | L. Dahan | A. Zaanan | J. Legoux | S. Manfredi | V. Hautefeuille | A. Turpin | E. Barbier
[1] O. Bouché,et al. Geriatric analysis from PRODIGE 20 randomized phase II trial evaluating bevacizumab + chemotherapy versus chemotherapy alone in older patients with untreated metastatic colorectal cancer. , 2018, European journal of cancer.
[2] C. Borel,et al. Bevacizumab Maintenance Versus No Maintenance During Chemotherapy-Free Intervals in Metastatic Colorectal Cancer: A Randomized Phase III Trial (PRODIGE 9). , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] J Ricke,et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.
[4] C. Borel,et al. Final results of PRODIGE 9, a randomized phase III comparing no treatment to bevacizumab maintenance during chemotherapy-free intervals in metastatic colorectal cancer. , 2016 .
[5] A. Hinke,et al. Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial. , 2015, The Lancet. Oncology.
[6] C. Punt,et al. Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group , 2015, The Lancet.
[7] R. Herrmann,et al. Bevacizumab continuation versus no continuation after first-line chemotherapy plus bevacizumab in patients with metastatic colorectal cancer: a randomized phase III non-inferiority trial (SAKK 41/06). , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.
[8] D. Shin,et al. Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial. , 2013, The Lancet. Oncology.
[9] J. Tabernero,et al. First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase III MACRO TTD study. , 2012, The oncologist.
[10] C. Tournigand,et al. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer--a GERCOR study. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] J. Hecht,et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] R. Greil,et al. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. , 2013, The Lancet. Oncology.